InMed Announces Results of 2025 Annual General and Special Meeting
InMed Pharmaceuticals (NASDAQ: INM) reported results from its annual general and special meeting held December 17, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
InMed Pharmaceuticals (NASDAQ: INM) reported results from its annual general and special meeting held December 17, 2025.
A total of 993,491 common shares (≈35.43% of 2,804,186 outstanding) were represented. All five director nominees were elected with roughly 81.9%–82.1% votes for. Shareholders approved CBIZ CPAs P.C. as auditors and approved the potential issuance of 20% or more of common shares under the amended Standby Equity Purchase Agreement with YA II PN, Ltd. The company filed the voting results on SEDAR+ on December 17, 2025.
Positive
- Director slate elected with ~82% shareholder support
- Shareholders approved CBIZ CPAs P.C. as auditors
- Authorization to issue ≥20% of shares under SEPA preserved
Negative
- 20%+ potential issuance creates clear dilution risk for holders
- Only 35.43% of issued shares were represented at the meeting
Details
News Market Reaction – INM
On Dec 18, the first trading day after this news, INM closed 7.50% above the previous close.
Data tracked by StockTitan Argus for the Dec 18 session.
Key Figures
- Shares represented
- 993,491 shares
- Common shares present in person or by proxy at the Meeting
- Participation rate
- 35.43%
- Portion of 2,804,186 issued and outstanding common shares
- Shares outstanding
- 2,804,186 shares
- Issued and outstanding common shares referenced for the Meeting
- Potential issuance
- 20% or more
- Approval under SEPA relative to Dec 13, 2024 share count
- Votes for Eric A. Adams
- 82.03%
- Support level for director election at the Meeting
- Votes for Andrew Hull
- 82.00%
- Support level for director election at the Meeting
- Votes for Nicole Lemerond
- 82.11%
- Support level for director election at the Meeting
- Votes for Neil Klompas
- 82.09%
- Support level for director election at the Meeting
Historical Context
-
Outlined potential negative impact of H.R. 5371 on BayMedica operations.
-
Reported lower BayMedica revenue, cash drawdown, and ongoing net loss.
-
Added experienced director John Bathery with extensive deal track record.
-
Appointed Neil Klompas, bringing capital-markets and biotech leadership expertise.
-
Reported revenue growth, cash runway into Q4 2026, and pipeline progress.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
standby equity purchase agreement financial
nasdaq listing rules 5635(d) and 5635(b) regulatory
sedar+ regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders held on December 17, 2025 (the "Meeting"), the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated November 3, 2025, were voted upon by the shareholders. A total of 993,491 common shares of the Company, representing approximately
Results of the vote for the election of the board of directors (the "Board") at the Meeting are set out as follows:
| Director | Votes For | Withheld Votes | ||
| Number | Percentage | Number | Percentage | |
| Eric A. Adams | 125,352 | 27,469 | ||
| Andrew Hull | 125,315 | 27,506 | ||
| Nicole Lemerond | 125,485 | 27,336 | ||
| Neil Klompas | 125,444 | 27,377 | ||
| John Bathery | 125,227 | 27,594 | ||
In addition, shareholders voted to approve CBIZ CPAs P.C. as the Company's auditors for the following year.
Shareholders also voted to approve the potential issuance of
InMed filed a report of voting results on SEDAR+ at www.sedarplus.ca on December 17, 2025.
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: ir@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release, and oral statements by the Company and its executive officers and directors, contain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information includes, but is not limited to, statements about H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act"), the impact of the Act on BayMedica Inc., any potential modifications to the Act and/or the timing thereof and the alternative options available to BayMedica and the Company, statements about developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, and statements about the potential issuance of common shares pursuant to the SEPA.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's business is disclosed in InMed's Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any other documents filed or furnished with the Securities and Exchange Commission available on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278446
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.